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The neuropeptide corticotropin-releasing factor (CRF) acts as a neurotransmitter in the central nervous system (CNS) to regulate the autonomic and behavioral responses to stress in addition to its role as a secretagogue in the hypothalamic-pituitary-adrenal (HPA) axis where it regulates the neuroendocrine stress response . CRF-containing neurons are distributed in cortical, limbic, and brain stem nuclei in the rat (Swanson et al., 1983) and primate (Foote and Cha, 1988; Lewis et al., 1989; Bassett and Foote, 1992) , with those CRF neurons in the amygdala and hypothalamus projecting to the medullary noradrenergic nuclei implicated in the CNS response to stress. The two CRF receptors in the CNS, CRF 1 and CRF 2 , are heterogeneously located, perhaps indicating unique roles for each in modulating neuronal systems (Chalmers et al., 1996) . Indeed, the discovery of urocortin, a second endogenous ligand for these receptors possessing a ten-fold greater affinity for CRF 2 , and several congeners, as well as a distribution to neuroanatomical sites preferentially expressing CRF2 mRNA, suggests a division into CRF-CRF 1 and urocortin-CRF 2 systems (Skelton et al., 2000b) .
There is ample evidence from animal models that modulation of central CRF systems play a role in stress responses. For example, central administration of CRF in rats produces behaviors associated with anxiety (Sutton et al., 1982; Dunn and Berridge, 1990) while CRF antagonists act as anxiolytics (Heinrichs et al., 1992; Rassnick et al., 1993) . Similarly, in non-human primates, central CRF administration produces symptoms of behavioral despair (Kalin, 1990) . Adverse early experience paradigms, developed to model mood and anxiety disorders in rodents and primates, produce altered CRF neuronal systems with changes persistent into adulthood (Sanchez et al., 2001 ).
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Alterations in CRF systems have also been found in patients diagnosed with mood and anxiety disorders. Patients with major depression (Nemeroff et al., 1984) and post-traumatic stress disorder (Bremner et al., 1997; Baker et al., 1999) exhibit elevated concentrations of CRF in cerebrospinal fluid. Similar to animal models of adverse early experience, childhood stressors such as abuse appear to cause persistent CRF system alterations that may contribute to psychopathology in adulthood (Heim et al., 2000; Kaufman et al., 2000) . Moreover, elevated cerebrospinal fluid CRF concentrations are normalized following treatment with antidepressants (Debellis et al., 1993; Veith et al., 1993) or ECT . These results have lead to the investigation of CRF receptor antagonists as potential novel therapeutic agents .
There is definitive evidence of HPA axis dysregulation in various bipolar disorders (Manji and Lenox, 2000) , and though there is no evidence to support changes in CSF CRF concentrations in euphoric mania (Berrettini et al., 1987; Banki et al., 1992; Risch et al., 1992) , central CRF systems are likely hyperactive in dysphoric or mixed mania as such patients exhibit marked HPA axis hyperactivity. Moreover, a strong relationship exists between bipolar disorders and childhood abuse (Pribor and Dinwiddie, 1992; Levitan et al., 1998; Agid et al., 1999; Hyun et al., 2000) , which as noted above, lead to lasting changes in CRF neuronal systems. Therefore, there are multiple lines of investigation to study CRF systems in bipolar disorder and its treatment.
Lithium is still considered the first line of treatment for manic depressive illness, and is approved by the US Food and Drug Administration for both acute and maintenance treatment. Divalproex sodium, a common formulation of valproic acid (VPA), is often effective in the significant population of patients non-responsive to lithium or unable to tolerate its side-effects (Nemeroff, This article has not been copyedited and formatted. The final version may differ from this version. prophylaxis and posses greater antidepressant effects than originally thought (Bowden et al., 1994; Bowden et al., 2000) . Moreover, VPA appears to be more effective in treating specific subsets of bipolar disorder including rapid-cycling, mixed bipolar disorder, and bipolar II disorder (Calabrese and Delucchi, 1990; Calabrese et al., 1992; McElroy et al., 1992; Bowden, 1998a; Keck and McElroy, 1998) .
Preliminary experiments from our laboratory suggest that subchronic (7 days) treatment with VPA alters CRF neuronal systems (Stout et al., 2001) . In the present studies, we sought to more thoroughly test the hypothesis that the mood altering effects of chronic (>2 weeks) VPA may be partially attributed to its effects on CRF neuronal systems, and to compare these effects to those were switched from standard rat chow to formulated chow containing either 22.5 g/kg valproic acid for 2 wks or 1.2 g/kg lithium carbonate for 1 week followed by 2.4 g/kg lithium carbonate for 2 weeks. Because step-up dosing over 3 weeks was required for lithium treatment compared to 2 weeks at a single dose for valproic acid, unique control groups were maintained for either two or three weeks. Animals in the lithium control and treatment groups were also provided with 0.9% saline ad libitium. Doses were chosen following a series of dose finding experiments in which serum drug concentrations were determined following 1week treatment (data not shown).
At the end of the dosing period, the rats were killed by decapitation between 0900 and 1030.
Trunk blood was collected for measurement of ACTH and corticosterone as well as drug concentrations; the brains were rapidly removed, frozen on dry ice, and stored at -80 °C.
Radioimmunoassays
ACTH radioimmunoassay. Trunk blood was collected on ice in EDTA-containing glass tubes and centrifuged for 10 min at 1500 x g at 4°C. ACTH was measured in duplicate plasma samples by a two-site immuoradiometric assay (Nichols Diagnostics, San Juan Capistrano, CA) with a coefficient of variation of 5% and sensitivity (blank + 2 SD) of 1 pg/ml. 
Drug concentrations
Serum drug concentrations were determined using radioimmunoassay for valproic acid and a Beckman ISE instrument with an ion-specific electrode for Li + by the Emory Medical
Laboratories.
In situ Hybridization
Serial coronal sections (20 µm) of the rat brains were prepared on a cryostat at -18 °C, thaw mounted onto SuperFrost Plus slides under RNAse-free conditions, and stored with Humi-Cap desiccant capsules at -80 °C until assayed. CRF, urocortin, CRF 1 , and CRF 2A mRNA in situ hybridization was performed as previously described in detail (Skelton et al., 2000a) .
CRF Receptor Autoradiography
Serial coronal sections (20 µm) of the rat brains were prepared on a cryostat at -18 °C, thaw mounted onto SuperFrost Plus slides under RNAse-free conditions, and stored with Humi-Cap desiccant capsules at -80 °C until the assays. CRF 1 and CRF 2A receptor binding autoradiography were performed as previously detailed (Skelton et al., 2000a Data analysis 3 animals were eliminated from the control VPA group for all analysis because their ACTH concentrations at the time of sacrifice were greater than 3 standard deviations from the mean for unknown reasons. Therefore, the number of animals analyzed in each group was as follows:
VPA control, n = 7; VPA, n = 10; lithium control, n = 10; lithium, n = 12. For each brain region examined, the mean treatment group desitometric value was compared to the appropriate mean control group densitometric value via a two-tailed t test. The mean treatment group densitometric value and SEM were then expressed as a percent of the mean control group densitometric value, 
HPA Axis Activity
Chronic VPA treatment resulted in a mean ACTH concentration of 90.4 + 24.7 pg/ml that was not significantly different than the VPA control group (54.3 + 15.6 pg/ml; Figure 1A) . Similarly, the mean corticosterone concentration in the VPA treatment group was 22.0 + 5.7 ng/ml, not significantly different than the control group (41.0 + 20.9; Figure 1A ). Figure   2A ). VPA significantly decreased CRF mRNA expression in the PVN (17%), but did not significantly alter CRF mRNA in the BNST or CeA. Lithium significantly increased CRF mRNA expression in the CeA (28%), but did not significantly alter CRF mRNA in the BNST or PVN.
Urocortin mRNA expression was measured in the Edinger-Westphal nucleus (EW, Figure 2B ).
Neither VPA nor lithium significantly altered urocortin mRNA expression.
CRF receptor mRNA expression and binding CRF 1 mRNA expression and receptor binding were examined in the basolateral amygdala (BLA) and frontal/parietal cortices (F/P CTX). Chronic VPA treatment significantly increased CRF 1 mRNA expression in the cortex (26%), but did not in the BLA ( Figure 3A ). In contrast, chronic VPA treatment significantly decreased CRF 1 receptor binding in the BLA (18%) and in the cortex (40%; Figure 3B ).
Chronic lithium treatment decreased CRF 1 mRNA expression in the BLA (27%), and in the cortex by (40%; Figure 3A ), but did not alter CRF 1 receptor binding in either region ( Figure 3B ).
CRF 2 mRNA expression and receptor binding were measured in the lateral septum (LS) and ventromedial hypothalamus (VMH). Chronic VPA treatment significantly decreased CRF 2 mRNA expression in the LS (24%) and in the VMH (23%; Figure 3C ), but did not significantly alter CRF 2 receptor binding in either region ( Figure 3D ).
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DISCUSSION
We have shown that chronic administration of the mood stabilizers valproic acid and lithium alters CRF neuronal systems, though the effects of VPA appear more widespread. The precise mechanism(s) of action of these drugs in producing their therapeutic actions remain obscure, but it is likely that effects on various pathways combine to produce their therapeutic effects. Placing the current data in the framework of the growing body of evidence implicating CRF system pathology in a number of psychiatric conditions, and the stabilization of these systems following successful psychopharmacological treatment, clearly suggests that mood stabilizers, and VPA in particular, may act in part through their effects on CRF neuronal systems.
Eliminating stressful procedures is a primary concern when designing studies measuring indices of CRF neuronal activity. Using rat chow as the means of drug administration eliminated possible activation of CRF systems through repetitive injections or implantation surgery and subsequent manipulation of minipumps. Based on the administration of divalproex sodium in patients via sprinkle caps (Keck and McElroy, 1998) and the delivery of lithium in rat chow (Lambert et al., 1999; Yuan et al., 1999) , preliminary trials were successfully conducted to test the feasibility of administering VPA in rat chow. Furthermore, initial concerns that a nonmetered dosing paradigm would result in a wide range of drug serum levels both between animals and diurnally proved to be unfounded as the range was actually quite limited (see Results).
In addition to utilizing non-stressful methodology, a primary goal of this dosing paradigm was to achieve drug plasma concentrations that fell within an expected therapeutic range for these drugs in psychiatric patients. Preliminary trials and previous work (Stout et al, 2001 ) indicated that rather high doses of valproic acid were needed to achieve such levels due to the extremely short half-life of valproate in the rat (~17 minutes). Both valproate and lithium administration were associated with decreased weight gain compared to control groups over the course of the experiment. This is distinct from the weight gain currently experience by patients treated with these agents and raises the questions as to whether the drug treatment rendered the animals ill.
However, drug treated rats did exhibit weight gain albeit less than controls, and all animals appeared overtly healthy.
The mean serum VPA concentration of 27.4 µg/ml is below the reported therapeutic range of 45 -100 µg/ml required for response in mania (Bowden et al., 1996) and as an anticonvulsant.
However, serum concentrations ranging from 20-45 µg/ml have been reported to be effective in treating cyclothymia and bipolar II disorder (Jacobsen, 1993) , subtypes of bipolar disorder reported to respond well to VPA treatment. Unpublished observations showed that the serum concentrations reported here for rats killed in mid-morning were ~2-2.5-fold higher in the late afternoon (~1600 hours). The average lithium concentration of 1.0 mmol/L was precisely within the recommended therapeutic serum concentration of 0.8-1.2 mmol/L (Lenox and Manji, 1998 ).
The effects of VPA and lithium on CRF neuronal pathways can be interpreted within an "antiparallel" stress system hypothesis, supported by several groups (Liebsch et al., 1999; Skelton et al., 2000a) , which posits that there are two central CRF stress systems with opposing effects. CRF released from neurons in the CeA and PVN acts upon CRF 1 receptors in the cortices, BLA, locus coeruleus (LC) and pituitary to coordinate the central nervous system response to stress. In contrast, urocortin released by terminals of neurons located in the EW nucleus is thought to act on CRF 2 receptors in regions such as the LS and VMH to regulate stresscoping behaviors. In addition to more classic pharmacological (Radulovic et al., 1999) evidence from transgenic mice strongly supports this hypothesis. For example, mice overexpressing CRF exhibit anxiogenic behaviors (Heinrichs et al., 1997) while those lacking the CRF 1 receptor exhibit decreased basal and stress-induced anxiety (Timpl et al., 1998) . In contrast, animals lacking the CRF 2 receptor exhibit increased anxiety-like behavior and decreased stress-coping behaviors (Bale et al., 2000; Coste et al., 2000; Kishimoto et al., 2000) .
Placing our results in this framework, the major effects of VPA appear to be in the CRF-CRF 1 pathway as opposed to the urocortin-CRF 2 pathway. VPA decreased CRF mRNA expression in the PVN and ultimately decreased CRF 1 receptor binding. This suggests that VPA may mediate its therapeutic effects in part by ultimately dampening the overall tone of the CRF-CRF 1 pathway.
Interpreted in this way, the effects of VPA would be similar to those of the benzodiazepine alprazolam. Previous results show that alprazolam alters CRF neuronal systems in accordance with the working hypothesis outlined above (Owens et al., 1989; Skelton et al., 2000a) , that alprazolam and VPA both increase GABAergic neurotransmission (Illig et al., 2000) , and are useful in the treatment of mania (Bowden, 1998b) . Therefore, one might have predicted that the effects of VPA on CRF systems would be similar to those of alprazolam.
Although we failed to detect an upregulation of the urocortin-CRF 2 pathway as observed with alprazolam, and in fact found a decrease in CRF 2 mRNA, this does not preclude the possibility that the effects of VPA on the CRF-CRF 1 pathway are therapeutically relevant.
The effects of lithium on CRF neuronal systems were less pronounced than those of VPA. There was a significant increase in CRF mRNA expression in the CeA and significant decreases in (Nemeroff, 2000) .
Moreover, patients are likely in different physiological states in distinct phases of the illness, as demonstrated by the study of rapid cycling patients (Juckell et al., 2000) . Therefore, it is quite probable that mood stabilizers exert their therapeutic effects through many different neural pathways depending on the state of the patient at a given time and the distinct pathways affected in that individual. We have shown that the mood stabilizers VPA and lithium do alter CRF neuronal systems in vivo, and based on these results posit that the therapeutic effects of VPA in particular may be mediated in part via these pathways. The continued development of tools to study CRF systems in vivo, either in animal models of affective disorders or the use of imaging techniques in bipolar patients (Soars et al., 2001) , will greatly assist in delineating the complex effects of these pharmacological treatments for bipolar disorders.
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